JP2014518216A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518216A5
JP2014518216A5 JP2014516067A JP2014516067A JP2014518216A5 JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5 JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5
Authority
JP
Japan
Prior art keywords
inclusive
insulin
concentration
composition
hyaluronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518216A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042816 external-priority patent/WO2012174478A2/en
Publication of JP2014518216A publication Critical patent/JP2014518216A/ja
Publication of JP2014518216A5 publication Critical patent/JP2014518216A5/ja
Pending legal-status Critical Current

Links

JP2014516067A 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤 Pending JP2014518216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161520962P 2011-06-17 2011-06-17
US61/520,962 2011-06-17
PCT/US2012/042816 WO2012174478A2 (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016200761A Division JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Division JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Publications (2)

Publication Number Publication Date
JP2014518216A JP2014518216A (ja) 2014-07-28
JP2014518216A5 true JP2014518216A5 (enExample) 2015-07-23

Family

ID=46513830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014516067A Pending JP2014518216A (ja) 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤
JP2016200761A Expired - Fee Related JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016200761A Expired - Fee Related JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Country Status (13)

Country Link
EP (1) EP2720712B1 (enExample)
JP (3) JP2014518216A (enExample)
KR (2) KR20140043438A (enExample)
CN (2) CN103974715A (enExample)
AU (2) AU2012271359B2 (enExample)
BR (1) BR112013032396A2 (enExample)
CA (1) CA2839511C (enExample)
EA (2) EA201400031A1 (enExample)
ES (1) ES2566549T3 (enExample)
IL (1) IL229749A0 (enExample)
MX (1) MX340172B (enExample)
NZ (2) NZ618331A (enExample)
WO (1) WO2012174478A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
PT2950780T (pt) * 2013-02-04 2020-07-07 Sanofi Sa Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素(insulin glulisine)的穩定調配物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
JP6562902B2 (ja) * 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
CN104095871A (zh) * 2014-07-10 2014-10-15 青岛蔚蓝生物股份有限公司 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液
WO2016011262A1 (en) 2014-07-16 2016-01-21 New York University Use of hyaluronidase for treatment of muscle stiffness
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
US20190382439A1 (en) * 2015-11-16 2019-12-19 Ubiprotein, Corp. Method for extending half-life of a protein
CN107789373A (zh) * 2016-09-06 2018-03-13 杏辉天力(杭州)药业有限公司 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
CN108070532A (zh) * 2016-11-16 2018-05-25 福建力多利生物科技有限公司 一种生产葡萄糖氧化酶的方法
WO2019050749A1 (en) 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
CN107918020B (zh) * 2017-11-15 2019-01-01 浙江夸克生物科技有限公司 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
TW202615652A (zh) * 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
WO2022141232A1 (zh) * 2020-12-30 2022-07-07 上海宝济药业有限公司 一种重组人透明质酸酶制剂及其应用
CA3236277A1 (en) * 2021-10-29 2023-05-04 Soon Jae Park Pharmaceutical composition comprising human hyaluronidase ph20 and drug
CN115820766B (zh) * 2021-12-28 2024-11-12 华熙生物科技股份有限公司 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4640210A1 (en) * 2022-12-23 2025-10-29 Hanmi Pharm. Co., Ltd. Formulation containing immunoactive interleukin 2 analog conjugate
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN117243852B (zh) * 2023-11-01 2026-05-19 华熙生物科技股份有限公司 一种皮肤外用组合物及其用途
CN117866931B (zh) * 2024-01-09 2026-08-07 江南大学 一种胞外分泌表达的透明质酸裂解酶及其重组菌与应用
CN119074669B (zh) * 2024-06-21 2025-04-18 邢珺月 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
EP0250119A3 (en) * 1986-06-20 1990-04-18 Vasocor Atherosclerotic anti-idiotype antibody immunoassay and reagents
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6559363B1 (en) * 1999-07-05 2003-05-06 Toyo Boseki Kabushiki Kaisha Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
ATE330938T1 (de) * 2000-05-19 2006-07-15 Alcon Inc Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
US6902548B1 (en) * 2001-03-19 2005-06-07 Ed Schuler Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
US20030125234A1 (en) * 2001-12-11 2003-07-03 Middaugh Charles Russell Alteration of protein stability
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ542729A (en) * 2003-04-23 2009-04-30 Hexima Ltd Isolation of a chymotrypsin, HpCh5, from Helicoveipa spp, characterised by its resistance to the proteinase inhibitors derived from Nicotiana alata
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
WO2005095625A1 (en) * 2004-03-31 2005-10-13 Hexima Ltd Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
WO2005118799A1 (en) * 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
WO2007047948A2 (en) * 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
AU2007281433A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
IL186598A0 (en) 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
PH12011502708B1 (en) * 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US20130022592A1 (en) * 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
SG11201403714TA (en) * 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof

Similar Documents

Publication Publication Date Title
US20240238382A1 (en) URI Agonist/Vasodilator
US11020459B2 (en) Factor VIII formulations
KR101978527B1 (ko) 펩티드 약물의 비경구 주입을 위한 안정한 제형
AU2007322334B2 (en) Method of drug delivery for bone anabolic protein
ES2566549T3 (es) Formulaciones estables de enzima degradante de hialuronano
CN1120019C (zh) 含NaCl的胰岛素制品
US20180036411A1 (en) Stable Formulation of Insulin Glulisine
JP2016503784A (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
KR20160105979A (ko) 인슐린-아연 복합체의 제조 방법
EP1706150B1 (en) Stable growth hormone liquid formulation
US20170189528A1 (en) Stable aqueous adalimumab formulation
US20210283259A1 (en) Protein formulations
KR20200037235A (ko) 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료
CA3011902C (en) Liquid insulin formulations and methods relating thereto
IL277721B2 (en) Medical infusion pump system for the delivery of an insulin compound
KR20130128658A (ko) 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법
WO2026096588A1 (en) Stabilized formulations of insulin and insulin analogs